Pharmacokinetics/pharmacodynamics  by unknown
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sponding times, blood samples were also obtained for quantification 
7Sowmw(n=ll) 12,1/6,7 6,68/3,2 3,213.0 15,617,) 13,519,O 
Crr. freundit(n=IO) 9,3/6,8 58,8/8.3 8,5/3,6 61.2/ 11,s 14,4/6,9 of T. T concentration in tissues was quantified by HPLC/MS assay, 
and the tissue/serum ratio determined in individual subjects. T was AOspp.(n=lO) 7,1/3,6 4,9/3.1 5,3/3,1 14,9/3,9 19,0/4,1 P.~m@msa(fl=ll) 3,3/3,2 7.7513.6 4,75/3,1 5,4/3,2 4,013.2 
TRXalont CEFJmc AMIdooc miCEF TRX+AMI 
Conclusions: Even in a high-risk environment with a highly 
LeXiuriclla-contaminated water supply system, legionnaires' disease 
can be prevented efectively by use of (i) water filter systems, (ii) 
screening for Legionella Ag in urine and (iii) pre-emptive antibiotic 
therapy in cases of Lqionella Ag detection in urine. 
Pharmacokinetics/pharmacodynamics 
lp76211 Serum bactericidal activities (SBA) and 
pharmacokinetics (Pk) of trovafloxacin (TRX) 
alone and in combination with cefepime (CEF) 
or amikacin (AMI) in healthy volunteers 
B. Urodersen', S. Ziege', G. Schreiber', K. Borner', P. Koeppe', 
H. Lode'. 'Department of Chest/l&tiuus Diseases, City Hospital 
Heekeshorn, 'Benjamin-Franklin Hospital, Freie Universith't Berlin, 
Berlin, Germarzy 
Objectives and methods: The optimal combination partner for fluo- 
roquinolones which could expand the antimicrobial spectrum and 
improve antimicrobial activity due to synergistic interaction is not yet 
known. Therefore we investigated ex vivo the SBA and Pk of TFX 
alone and in Combination with CEF or AMI. 12 healthy volunteers 
(age: 25.15f2.6 years, mean 70.4214.4 kg) received over 1 h infu- 
sions of either 300 mg T K X  alone, 2000 mg CEF alone, 6 nig/kg 
AM1 alone or T R X  in Combination with CEF or AM1 at the same 
doses. SBAs were determined at 1, 10 and 24 h by a standardized 
microdilution method (NCCLS 1992) against 42 clinically isolated 
strains. Serum and urine concentrations of the three antibiotics were 
measured by HPLC or a fluorescence polarization immunoassay 
(AMI). 
Results: At the end of a 1-h infusion, the mean concentration of 
TFX alone was 4.63% 1.1 1 nig/L, and the concentrations of TFX in 
combination with AM1 or CEF were similar (4.72zk0.88/4.24? 
1 .16).The Pk parameters also showed no differences between single 
and combined administration ofTFX. The mean reciprocal titers for 
1 h /10 h 
and completely hydrolyzed to T in humans. Antibiotics must distrib- 
ute to the site of action in suficient concentration to be effective. 12 
subjects (age 37-70 years; weight 50-95.5 kg) received one dose of 
alatrofloxacin at a T equivalent dose of 200 mg 1-8 h prior to surgery. 
Colonic tissue, peritoneal fluid and blood samples were collected 
0.5-15 h after dosing for determination of T concentrations. The 
tissue/serum ratio for T was calculated for each subject. T distrib- 
uted rapidly into colonic tissue, achieving concentrations of 1.4 mg/g 
at 1.4 h, 2.8 mg/g at 2 h and 1.0 mg/g at 9.6 h after dosing. The 
mean T tissue/srrum ratio over the study duration was 0.74. In peri- 
toneal fluid, the maximum concentration of T (2 mg/L) was 
observed between 1.4 h and 2.2 h post-infusion. The mean peri- 
toneal Auid/serum concentration ratios at the times of incision, 
colonic tissue collection, and peritoneal closure, were 0.21, 0.43 and 
0.49. T was well tolerated by all subjects. The5e results indicate that 
one dose of T given prior to surgery rapidly distributes into colonic 
tissue, achieving concentrations similar to those in seruin 2-10 h 
post-infusion. In addition, T also distributes readily into peritoneal 
fluid. In both tissues, concentrations achieved are several times the 
MICw of several susceptible organisms. 
lp764/ Penetration of trovafloxacin into lung tissue, 
skeletal muscle, bone and skin in subjects 
undergoing thoracotomy 
K. Rolston', L. Dogolo', S. Willavize', J. Vincent'. 'M.D. 
Anderson Cancer Centev, Houston, T X ,  USA; 'P'zer Central Research, 
Groton, C?; USA 
Trovafloxacin (T) is a unique fluoroquinolone antibiotic with in vitro 
activity against atypical, Gram-negative, and Gram-positive respira- 
tory pathogens, including penicillin-resistant pneumococci, anaer- 
obes and kgionella species. Its long half-life and extensive tissue 
penetration permit once-daily dosing. Penetration of T into respira- 
tory tract and other tissues was evaluated in subjects undergoing 
thoracotomy. 11 subjects took T 200 nig o.d. for 3 days prior to 
surgery at predetermined times between 2 and 27 h after the last dose. 
Open biopsy specimens of lung tissue, skeletal muscle, bone, subcu- 
Conclusions: The combination of T R X  with CEF or AM1 was 
more active than the antimicrobial agents given alone. CEF was the 
more active combination partner for TRX;  however, activity against 
P aerryinosa was only nioderate with all single or combined antibi- 
otics. 
(p763j Colonic tissue and peritoneal fluid 
concentrations of trovafloxacin in patients 
undergoing colo-rectal surgery 
G. Melnik', W.H. Schwesinger , L.C. Dogolo', J. Vincent2. 
'The University 91 Exas Health Science Center, San Antonio, TX,  
USA; 'l'jizer Ccritral Researrh, Groto,i, C?; U S A  
Trovafloxacin (T) is a fluoronapthyridone related to well-known 
fluoroquinolone antibiotics. In contrast to other quinolones, T 
possesses activity against Enterobacteriaceae, Gram-positive organ- 
isms, including S. pneumoniae, and anaerobes, including B. jagi l is .  Its 
long terminal half-life suggests the feasibility of once-daily dosing. It 
i s  available in IV form as a prodrug (alatrofloxacin). which is readily 
the last dose were 2.1k1.2 mg/g in lungs, 1 .550.6 mg/g in skeletal 
muscle, 0.96k0.4 mg/g in bone, and 0.44k0.44 mg/g in skin, 
resulting in a tissue/serum ratio of 2.0 in lungs, 1.5 in skeletal muscle, 
1.0 in bone and skin and 0.4 in subcutaneous tissue. These results 
indicate that T achieves Concentrations several-fold higher than the 
MIC90 of the pathogens responsible for respiratory tract and other 
common infections in humans (e.g. S. prieumorriac 0.06-0.25 mg/L, 
H .  ir$uenzae 0.0084.03 mg/L, L. pneumophilia 0.008-0.06 mg/L, 
M. pneumoniae 0.25 mg/L, and S. aweus 0.03-0.12 nig/L. 
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(p7651 Comparative antimicrobial effects of 
trovafloxacin and ciprofloxacin on 
Streptococcus pneumoniae in an in vitro 
dynamic model: MICso-based prediction of the 
equiefficient doses 
S. Zinner', D. Gilbert', K. Simmons', 0. Kononenko', A. Firsov2. 
'Roger Wiltiams Medical Center and Rhode Island Hospital, Brown 
University, Providence, Rl, USA;  Centerfor Science and Echnoloa, 
LekBioTech, Moscow, Russia 
Objectives: To compare the antimicrobial effects (AMEs) of 
trovafloxacin (TR) and ciprofloxacin (CI) on differentially suscepti- 
ble strains of S. pneumoniae (S.P.) in terms of dose (D)-response 
curves. 
Methods: Three clinical isolates of S.p. with MIC~l<=0.125, 
0.125 and 1 pg/mL and MICci=l, 1 and 32 pg/mL were exposed 
to TR (as a single dose) or CI (two doses with a 12-h interval). 
Following an initial first-order increase, monoexponentially decreas- 
ing concentrations of TR or CI with half-lives of 8.2 and 5.1 h, 
respectively, were simulated in peripheral compartments of the 
model. The ratios of area under the concentration-time curve (AUC) 
in the central compartment to the MIC ranged from 18 to 100 and 
from 12.5 to 50 (pgxh/mL)/(pg/mL) for TR and CI, respectively 
Results: The intensity of the AME (IE) of TR and CI correlated 
with log AUC/MIC (?=0.89 and 0.87, respectively). Based on the 
bacterial strain-independent IE-log AUCIMIC relationships, the 
AMEs which might be produced by 24-h Ds ( 0 2 ,  h) of TR and CI 
were predicted for a hypothetical representative of S.p. with MIC 
corresponding to the MIC5n. With TR,  the IE-log 0 2 4  h curve was 
positioned to the left of that with CI, showing that a lower 0 2 4  h of 
T R  might provide the same AME. For example, to achieve the AME 
of the clinically accepted 200 mg 0 2 4  h of TR, the 0 2 4  h of CI would 
be far in excess (2X 1544=3088 mg) of what can be given clinically 
Conclusions: The described approach to the comparison of 
quinolones might be useful to predict the antimicrobial effects of 
other quinolones. 
(p7661 Comparative antimicrobial effects of 
ciprofloxacin (CI), SB 265805 (SB) and 
trovafloxacin (TR) on Staphylococcus aureus in 
an in vitro dynamic model 
0. Kononenko', S. Vostrov', I .  Lubenko', S. ZinneZ, A. Firsov'. 
' Centerfor Science and Echnolofx LekBioTech, Moscow, Russia; 'Brown 
University, Providence, RI, U S A  
Objectives: To demonstrate the impact of different pharmacokinet- 
ics of CI, SB and TR on their antimicrobial effects (AMEs). 
Methods: Two MRSA with different susceptibilities to CI, SB 
and T R  (MICcrs=0.3 and 1.25, MICsBs=O.Ol and 0.04 and 
M 1 C ~ ~ s = 0 . 1 5  and 0.6 pg/mL) were exposed to decreasing concen- 
trations ofCI (two 12-h doses, T w z = ~  h), SB or TR (both as a single 
dose, T1/zs=7.4 and 9.2 h, respectively) over %fold ranges of the 
AUC/MIC ratio: 116-932 (CI) and 58-466 (pgXh/mL)/ 
(pg/mL) (both SB and TR). 
Results: Linear relationships between intensity of the AME (IE) 
and log AUC/MIC were bacterial strain independent and were not 
superimposed for C1, SB and TR ( P 0 . 9 9  in each case). At a given 
AUC/MIC 100 including the Schentag's 125 (pgx h/mL)/(pg/mL), 
T R  and SB had 28% and 6% greater AMEs than CI, respectively. 
However, the AMEs of a 200-mg dose of T R  and a 400-mg dose of 
SB on a hypothetical strain of S. aureus with MICTR=MIC~~=O.O~ 
and MIcs~=MIC50=0.016 pg/mL would be very similar: 370 and 
360 (log CFU/mL) X h, respectively. 
Conclusions: Both TR and SB might be even more efficient 
against S. aureus than might be expected considering the differences 
among the MICs of TR or SB and CI. Due to the strain-indepen- 
dent pattern of the &log AUCIMIC relationships, these conclusions 
might be relevant to other representatives of the same species. 
/p7671 Comparative antimicrobial effects (AMEs) of 
ciprofloxacin (CI) and trovafloxacin (TR) on 
Pseudomonas aeruginosa in an in vitro 
dynamic model 
I. Lubenko', S. Vostrov', 0. Kononenko', S. Zinne?, A. Firsov'. 
'Center for Science and Technology, LekBioTech, Moscow, Russia; ZBrown 
Univerrity, Providence, RI, U S A  
Objectives: To compare the AMEs of CI and T R  in terms of the 
AUC/MIC and dose (D)-response relationships. 
Methods: Three clinical isolates off? aeruginosa (Fa.), Pa. 282, 15 
and 842, with MICc[s=0.09, 0.15 and 0.75 and MIC~1<s=0.15, 0.3 
and 1.25 pg/mL, respectively, were exposed to decreasing concen- 
trations of CI (two 12-h doses Ti/z=4 h) or TR (as a single dose: 
T1/2=9.2 h). The AUC/MICs ofCI ranged from 58 to 936 and those 
of TR from 55 to 466 (pgXh/mL)/(pg/mL). 
Results: The intensity of the AME (IE) correlated well with log 
AUCIMIC for both CI and TR in a strain-independent fashion, 
although the IE-log AUC/MIC plots were specific for CI and TR 
(?=0.99 and 0.95, respectively). Based on the respective IE-log D 
curves, a clinically accepted 24-h D ( 0 2 4  I,) of CI (2x500 mg) was 
8% less efficient than 0 2 4  h of TR (200 mg) against Pa. 282 but 19% 
more efficient against Pa. 15. With P.a. 842, the greater efficacy of 
CI was more pronounced, although the highest clinically relevant D24 
hs of both CI (2x750 mg) and T R  (300 mg) provided much lower 
IES than with the more susceptible P.a. 282 and Pa. 15. 
lp7681 Prediction of the breakpoints of equiefficient 
ratios of area under quinolone 
concentration-time curve (AUC) to MIC of 
trovafloxacin relative to ciprofloxacin and their 
equiefficient 24-h doses using an in vitro 
dynamic model 
S. Vostrov', 0. Kononenko', I. Lubenko', J. Portnoy', S. Zinner', 
A. Firsov'. 'Centerfor Science and Technolofl, LekBioTeck, Moscow, 
Russia; 'Brown University, Providence, Rl, U S A  
Objectives: To examine whether rdationships between AUC/MIC 
and the antimicrobial effect are bacterial strain and species indepen- 
dent, and to predict the equiefficient AUC/MIC breakpoint for 
trovafloxacin (TK) relative to ciprofloxacin (CI) and their equieffi- 
cient 24-h doses ( 0 2 4  h). 
Methods: Three clinical isolates of Sfaphylococcus aureus with 
different MICs and one isolate each of Escherichia coli, Kkbsiella pneu- 
moniae and Pseudomonas aeruginosa with similar MICs were exposed 
to decreasing concentrations of T R  or CI with half-lives of 9.25 and 
4 h, respectively. With each organism, single doses of T R  and two 
12-h doses of CI were designed to provide wide ranges of the 
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Parameter Plasma (HPLC) Saliva (HPLC) 
AUC (mg'hll) 35.111.20 38.911.19 37.711 S O  32.811.22 
C ,,,=(mgIL) 3.0511.21 3.8711.28 3.62l1.60 4.5611.56 
t m a  (h) 1.4511.75 1.4111.70 1 .6011.58 1.7311 .50 
t % (h) 10.511 .I2 16.111.27 19.3l1.81 15.811.34 
MRT (h) 15.011.14 18.011.14 26.111.80 19.111.22 
VJf (Ukg) 2.1111.15 2.9211.39 3.6211.38 3.3911.45 
CUf (Uh) 11.411.20 10.311.19 10.811.50 12.2l1.22 
dayl  day7 dayl  day7 
.. . . . - . - - . . . . . . - - 
AUC/MIC, 54-466 and 59-932 (pgx h/mL)/(pg/mL) of T R  and 
CI, respectively. 
Results: With both T K  and CI, intensity of the antimicrobial 
effect (6) correlated well with log AUC/MIC in a bacterial strain- 
and spec~es-independent fashion, although the I~-log AUC/MIC 
plots were specific for T R  and CI (?=0.94 and 0.96, respectively). 
At any given AUC/M[C ratio including Schentag's 
AUC/MIC= 125 (pgxh/mL)/(pg/niL) reported as the breakpoint 
value f o r  CI, the IE of TK was 30% greater and the equivalent 
AUCIMIC breakpoint for TR (7 1 (pgxh/mL)/(pg/niL)) was lower 
than for CI. Based on the &-log AUC/MIC relationships, the 
equieficient DX 1,s of T R  and CI were predicted for hypothetical 
representatives of the studied bacterial species with MICs corre- 
sponding to the MlCj~s .  
Conclusions: The suggested methods might be used for in vitro 
prediction of the antimicrobial potentials of newly developed fluo- 
roquinolones. 
1 P769 Multiple-dose pharmacokinetics (Pk) of 
moxifloxacin (MOX) in serum, urine and saliva 
m1 Pharmacodynamic parameters of moxifloxacin 
K.E. Milnr, F.M. MacKenzie, I.M. Gould. :Medical Mirrubioh%y, 
Aberdcwri Royal Infirniary, Aberdecn, L'K 
The pharmacodynamics of moxifloxacin were measured for 16 
isolates; 4XEnterobacteriaceae; S. aurens 2 X resistant (R) and 
2Xsensitive (S) to niethicillin; H .  i@rrnzne 2 X K  and 2XS to 
ciprofloxacin; and S. pncumotiiaiz 2 X R  and 2XS to penicillin. 
MlCs including inoculum effect, time kill curves, PAE, PA-SME, 
SME and CERT were determined. The tiiininial effective dose 
(MED) was calculated from the kill for particular AUIC values, PA- 
SME and time for regrowth to starting inoculum. An AUC(0-24) of 
30 mg.h/L for moxifloxacin (400-mg dose) translates into a nieaii 
clinically achievable AUIC value for the test isolates of 574 (range 
3.75-962). Pharniacodynamic paranieters were established at AUIC 
values of 2.4-240. Moxifloxacin kill was concentration dependent. 
At AUIC values of 96 and 240, all isolates demonstrated kill which 
increased over 0-6 h; mean reduction in CFU/mL at  6 h was 2.52 
(range 1.37-4.40). AUIC=2.4 did not result in decreases in 
CFU/mL over 0-6 h, although growth was slower. Mean CERT 
values of 4.44, 2.87, 1.00 and 0.09 h were obtained for AUICs of 
240, 96, 24 and 2.4. They increased by an average of 11% with 
persisting sub-MIC levels. 
Conclusions: Moxifloxacin exhibited concentration-dependent 
bactericidal activity which was inoculum dependent on both Grain- 
negative and Gram-positive organisms as well as significant PAE and 
CERT values. At MICs <0.3 iiig/L, an MED is likely to be achieved 
with a 400-mg dose. This may have implications for setting thc 
breakpoint of moxifloxacin. 
No dose adjustment is needed for moxifloxacin 
(MOX) in subjects suffering from hepatic 
impairment (HI) 
H. StaR', D. Kubitza', K. von Bergiiann', A. Halabi', J. 
Kuhlmann', T. Sudhop'. 'Bayer AG, Wirppertal, 'Uwiuersity .f,f~oriri, 
B o n n ,  -'Clin-Pharnia Research, Kid, Germnrzy 
In an open, multiple-center, single-dose (SD), non-controlled. yaral- 
lel-group comparison the influence of HI on pharniacokinetics (PK) 
ofMOX and metabolites M I ,  M2 after a 400-mg oral SD was inves- 
tigated in 18 male subjects ( to healthy subject5 (HS), 8 patients with 
HI due to cirrhosis), 49.6? 10.9 years of age. The severity of the HI 
was mild to moderate (Child-Pugh A in 6/8, B in 2/8 patients). 
Plasma and urine concentration5 of MOX, M1 and M2 were deter- 
mined using a validated HPLC method. The main PK parameters of 
MOX for both groups are (geometric mean, standard deviatic 
median (range) for f,&: 
AUC mg'hlL 32.81 1.3 25.1 11.3 
Cmax mglL 3.01 1.3 2611.4 
t./, h 13.41 1.2 11.7 11.4 
CUf Llh 12.211.3 16 0 11.3 
h 0.75 (0.5 - 3.0) 0.5 (0.5 - 2.5) tmax 
The drug was well tolerated in the study. In comparison to the 
HS, HI patients had slightly lower plasma concentrations, C,,,.,, and 
AUC. There was no obvious difference with regard to t,,,,,, fl,?, or 
CLII. The increased oral clearance in HI patients was associated with 
increased N-sulphonation (Ml) ,  indicating enhanced clearance 
and/or reduced bioavailability by presystenilc metabolism. This was 
considered as clinically not relevant, due to Mls  lacking bxtericidal 
activity and high protein binding $, - 10%). PK of M2 (glucuroinde) 
were not significantly different to those of HS. No dose adjustment 
is needed for MOX in subjects cuffering from HI. 
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[ml Pharmacokinetic/pharmacodynamic estimates 
for the treatment of community-acquired 
respiratory tract infections (CA-RTII with 
moxifloxacin (MOX) 
H. Stass, A. Prove. Bayer AG, Wuppertal, Germany 
The development of a drug for the treatment of CA-RTI requires a 
thorough investigation of the pharmacodynamic and pharmacoki- 
netic variability expected for the target population. This paper 
describes the considerations undertaken to allow optimization of 
dosing schedules for the clinical development. 
The distribution of AUC and C,,,,, data obtained for a 400-mg 
dosing regimen during phase I was described by means of statistical 
methods. The data ranges and means of the pharmacodynamic surro- 
gate parameters C,,,,,/MIC and AUIC known to be predictive for 
the antibacterial activity of quinolones were calculated according to 
Schentag for different dose regimens of MOX. The PK/PD para- 
meters (using M1C~js of S. pneumoniae as representative examples for 
the target organisms) resulting from the pharmacokinetic distribution 
are summarized below. 
A 400-mg dose of MOX offers an excellent antimicrobial profile 
against susceptible Gram-positive pathogens like S. pneumoniae and 
Gram-negative bacteria like K. pneumoniae. For the 400-mg dose, 
even the lower extreme of the observed distribution range is beyond 
the cut-off points specified in the literature. This suggests that the 
required concentratioii-time range for individuals is fully covered 
with a 400-nig dose given once a day. 
)p773) Pharmacodynamic activity of moxifloxacin in 
an in vitro model against Gram-positive and 
Gram-negative pathogens 
8. Wiedemann. Pharmaceutical Microbiology, University o f  B O M ~ Z ,  Bonn, 
Germany 
Objectives: To compare the pharmacodynamic activity of moxi- 
floxacin with that of grepafloxacin we used the kill kinetics after 
simulation of the pharmacokinetics in an in vitro model with rele- 
vant human pathogens. 
Methods: In an in vitro dilution model we simulated the phar- 
macokinetics of a 400-mg oral dose of moxifloxacin and measured 
the activity against S. pneumoniae, S. pyogenes, H .  itzjuenzae, M.  
catarrhalis and K. pneumoniae. As a comparative drug, we used 400 mg 
grepafloxacin. During the 24-h experimental period we measured 
the bacterial count. The concentration of the drug was controlled by 
a bioassay using K. pneumoniae C R  1 as test organism. 
Results: The simulation of the 400-mg moxifloxacin dosage 
resulted in a steady killing of all three S. pneumoniae strains used. The 
maximal reduction was 4.5-5.5 logs after 24 h. There was no differ- 
ence in the killing activity, whether the strains were resistant or sensi- 
tive to penicillin or macrolides. The killing of Gram-negative bacteria 
was much faster; for example, the bacterial count of M .  mfarrhalis was 
reduced by 5.5 logs within only 4 h. None of the strains showed 
regrowth within the 24-h period after the application ofa single 400- 
mg dose. Grepafloxacin was slightly less active against S.  pneumoniae 
and M .  catarrhalis, but of equal activity against the other pathogens. 
Conclusions: Moxifloxacin, in contrast to older quinolones like 
ofloxacin or ciprofloxacin, combines high bactericidal activity against 
Gram-negative bacteria with excellent eradication of Gram-positive 
bacteria with a single dose within 24 h. 
m1 Penetration of fleroxacin into ischemic tissues 
PA. Miglioli', R. Kafka', E Allerberge?, R.M. Gaion'. 
'Deportment cf Pharmacology, University of Padova, Italy; lnsfitlrte o f  
Hygiene, University o f  lnnsbruck, Austria 
Objectives: Comparison of fleroxacin (FLX) distribution into 
ischemic versus normal tissues. 
Methods: Thirteen patients undergoing elective reconstructive 
surgery for peripheral vascular disease were studied. Each patient was 
given FLX 400 mg, IV bolus. Two hours after drug administration, 
venous blood and samples from normal and ischemic tissues (muscle, 
bone, subcutaneous fat and tendon) were collected. Serum was sepa- 
rated by blood centrifugation and tissues were homogenized. FLX 
assays were performed using agar plates seeded with Escherichia coli 
Kp 5124. 
Results: Mean serum level (mg/L) was 6.2324.39. In normal and 
ischemic tissues, FLX levels (mg/g) were, respectively: muscle 
4.27k2.79 and 2.2821.14, subcutaneous fat 2.83-tl.65 and 
3.0923.97, tendon 2.8422.04 and 3.50*3.23, and bone 1.8921.76 
and 2.2522.77. 
Conclusions: These results show a good diffusion of FLX into 
ischemic tissues. Thus the drug can be useful for treatment or 
prophylaxis of infections sustained by sensitive bacterial strains in 
these tissues. 
[p7751 In vitro pharmacodynamics of levofloxacin 
K.E. Milne, EM. MacKenzie, I.M. Gould. Medical Microbiology, 
Aberdeen Royal Infirmary, Aberdeen, UK 
PAE, PA-SME, CEKT and adaptive resistance (AD) were measured 
after exposing 11 strains to levofloxacin (LEV). The strains included 
5 Gram-negatives (GNs), 2 penicillin-resistant pneumococci (PRP), 
and 2 methicillin-sensitive and 2 methicillin-resistant S. aureus 
(MSSA and MRSA). Ofloxacin (OFL) was used as a comparator for 
Gram-positives (GPs) and ciprofloxacin (CIP) for GNs. Methods 
included impedance monitoring (IMP), viable counts (VC), biolu- 
minescence (BIOL), light microscopy (LM) and electron microscopy 
(EM). PAE, CERT and time kill curves were concentration depen- 
dent. PAE and kill curves were method dependent but CERT was 
not. At 10XMIC, LEV mean PAE values (h) by BIOL/IMP (and 
VC/IMP) were 9.0 (3.3). 4.5 (1.8) and 2.3 for GNs, MSSA/MRSA 
and PRPs respectively. CERT values were 9.8 and 4.7 h for GNs and 
MSSA/MRSA respectively. PAE and CERT were longer for LEV 
compared to the comparators. Persisting sub-MIC levels significantly 
increased the PAE with PA-SME values up to 13.7 h. For 
MSSA/MRSA mean loglo kill ofLEV at 6 h with 1 XMIC was 1.72 
and at l0XMIC after 24 h was 5.0. AR was not exhibited for LEV. 
LM and EM after 2 h of LEV exposure showed little morphologic 
change in GPs with some lengthening of GN bacilli. 
Conclusions: LEV is rapidly bactericidal with a long concentra- 
tion-dependent PAE, PA-SME, SME and CERT. While there were 
method-dependent variations in dynamic parameters, which need 
further investigation, CERT was independent of method. The lack 
of adaptive resistance suggests that flexibility can be allowed in dosing 
regimens. 






/p776\ Comparative pharmodynamic activity of 
grepafloxacin and macrolides in an in vitro 
model against respiratory tract pathogens 
16231-50.9 93.84-3.8 53.44-272 27.5%-19.0 16+/- 13.6 
14.14-43 724-23 3.8+/- 1.4 13+/-0.6 1.5+/-22 
6511-37 14.8+/-133 115+/-5 7.64-5.4 42+/-2.4 
0.6+/- 0.5 1.2 +/- 13 0.9 % 0.8 0.7 +/- 05 0.4 +/- 02 
B. Wiedeniann, E. Pfeil, I. Wiegand. Pharmaceutical Microbiology, 
University of Bonn, Bonn, Germany 
Objectives: To compare the pharmacodynaniic activity of grepa- 
floxacin with macrolides we used the kill kinetics after simulation of 
the pharniacokinetics in an in vitro model with relevant respiratory 
tract pathogens. 
Methods: In an in vitro dilution model we simulated the phar- 
niacokinetics of a 400-nig oral dose of grepafloxacin and measured 
the activity again\t S. pneumornae, H.  influenzae and M.  catarrhalis. As 
comparative drugs we used 300 mg roxithronlycin and 250 ing clar- 
ithromycin. For the latter drug we simulated serum and lung phama- 
cokinetics. During the 24-h experimental period we measured the 
bacterial count. The concentration of the drug was assessed by a 
bioassay using K. pnrumorziae C R I  as test organism. 
Results: The simulation of the 400-mg grepafloxacin dosage 
resulted in a steady killing of all strains used. The maximal reduction 
was more than 6.5 logs after 24 h. Neither macrohde was able to 
reduce the bacterial count of H. ircpirenzne. In contrast, after 24 h an 
increase of 1-2 logs was observed. S. pneuwoniae was not reduced 
within the first 12 h, but was decreased by 2-3 logs after 24 h. 
Moraxclla catarrhalis was reduced by more than 6 logs by roxithro- 
mycin but only by 2 logs by clarithromycin, even with superior kinet- 
ics in the lung. 
Conclusions: Grepafloxacin, in contrast to macrolides, combines 
high bactericidal activity against Gram-negative bacteria with excel- 
lent eradication of Grain-positive bacteria with a single dose within 
24 h. 
lp7771 Pharmacokinetics of amoxycillin-clavulanate in 
bronchial secretions after multiple doses to 
intensive care patients 
E Jehl', J.D. Pete?, J.M. Engler', 0. Mimoz', J.C. Rigolot2, G. 
Brami'. 'Laboratory ($Antibiology of the Institute of Bacteriology, 
'Department of Anes thes i~~log~ University Hospital of Sfrasboug, 
Strasbouy, 3Bicetre University Hospital, Le Kremlin Bicetre, 'SmithKline 
Beechain L . P ,  Nanterre, France 
The pharmacokineticc of aiiioxycillin-clavulanate (AMX-CA) were 
studied in seven mechanically ventilated intensive care patients (seven 
males, age 57.4k16.7 years, anti weight 57.325.6 kg) (meanskstan- 
dard deviationc) with bacterial pneumonia. They were given intra- 
venous doses of amoxycillin (2 g) and clavulanate (0.2 g) as 30-min 
infusion? every 6 h. The kinetic study was performed at the third day 
of treatnient after the 9th dose. Samples of blood and bronchial secre- 
tions (BS) were collected before and 0.5, 1 ,  2, 4 and 6 h after the 
start of infusion. Drug concentrations in both sera and BS were 
measured by high-performance liquid chromatography. Concentra- 
tions in serum (SE) and BS for AMX and CA were as follows (in 
mg/L): 
u.3 1 L 4 
These data indicate good penetration ofboth drugs into BS. Their 
extent of penetration in BS, as defined by the area under the curve 
(0.5-6 h) ratio, were 17.8% (AMX) and 22.4% (CA) respectively. 
Considering an AMX MIC of 2 mg/L (which includes 98% of S. 
ptiennzoniae strains isolated in France), the times above MC in both 
serum (Se-T>MIC) and BS (BS-T2MIC) are 100% for 2.2 g t.i.d. 
The concentrations of CA in BS are persistent and high enough to 
exceed the values (0.120. 0.010 and 0.10 mg/L respectively) found 
to be effective in vitro against 6-lactanlases produced by the most 
important R-lactamase-producing pathogens responsible for commu- 
nity-acquired pneumonia (H .  influenzae, M .  catarrhalis, methicillin- 
susceptible S. aureus), leading to high in situ 8-lactanlase inhibitory 
quotient (3-120). 
Lp7781 Pharmacodynamics (PDs) of amoxycillin 
(AMX)-clavulanic acid (AC) 1.125 g orally 
against 8-lactamase-producing Haemophitus 
influenzae (HI) 
E Jehl, D. Ponipei, N. Dhoyen, H. Monteil. Laboratory of 
Antibiology of the Institute of Bacteriology, University Hospital of 
Strasbuiug Strasbouy, Francr 
The purpose of this work was to investigate the PDs and the bacte- 
ricidal activity of AMX-CA administered as a single 1125-g oral dose 
to 12 volunteers against one strain of RL (+) HI (AMX MIC=8 
mg/L ; AMX MBC=128 ing& AMX-CA (2 mg/L) MIC=0.25 
mg/L; AMX-CA MBC=4 mg/L). Mean serum concentrations 
(HPLC assay) ranged from 17.7 mg/L (peak at T,,,,,=1.5 h) to 0.25 
mg/L (trough level at 12 h) for AMX and from 2.35 mg/L (peak) to 
<0.05 (trough) for CA. The kinetics of bactertcidal activity were 
investigated at 0.5, 0.75, 1, 1.5, 2.5, 5, 8 and 12 h after drug intake. 
The ex vivo bactericidal activity of all samples diluted 1/2, 1/4 or 
1/8 is rapid (about 3 h) and corresponds to either a 6 log decrease of 
the starting inoculum for samples 0.5 h and 0.75 h, or a 5 log decrease 
for samples 1 h to 8 h, or a 3 log decrease for the 12-h samples. There 
is no correlation between the antibiotic concentrations and the index 
of surviving bacteria (ISB), indicating that AMX acts against HI 
according to a time-dependent mechanism. Time above MIC is 
100% of the dosing interval (12 h). The concentration correspond- 
ing to the maximal efficacy (MEC) (i.e. corresponding to an ISU of 
20%) is 0.5 mg/L and is reached during 80% of the 12-h interval. 
These data constitute an interesting prerequisite to the use of AMX- 
CA 1.125 g orally every 12 h. 
)p7791 Ex vivo pharmacodynamics (PDs) of 
intravenous (IV) amoxycillin (AMX)-clavulanic 
acid (AC) against 8-lactamase (8L)-producing 
E. coli in a Yucatan micro-pig model that 
mimics human pharmacokinetics (PKs) 
E Jehl, D. Pompei, J.D. Peter, V Murbach, Y Salmon, N. Dhoyen, 
J. Salmon, H. Monteil. Laboratory o f h r i b i o l o g y  u f t h e  Institnte C$ 
Bacteriology, University Hospital of Strasbourg, Strasbourg, France 
In order to investigate the ex vivo bactericidal activity of AMX-CA 
against RL-producing E. coli in a Yucatan micro-pig model, the simi- 
larity of both drugs' PKs in humans and pigs was first verlfied. Four 
adult pigs (mean weight: 25 kg) received a single dose of 1.1 g AMX- 
CA IV to mimic the 2.2-g IV dosage regimen in humans. PKs for 
humans (historical data at 2.2 g IV) and pigs respectively are: C,, 
110 and 146 mg/L; AUCIH, 125 and 115 mg.h/L; T112, 1.03 and 
1.0 h for AMX; and C,,,,, 13 and 11.3 m g / k  AUGM, 18.2 and 12.5 
mg.h/L; TI/z, 0.8 and 1.0 h for CA. Thus, this model is quite suit- 
able for in vivo/ex vivo PD investigations. Two strains of E. coli (low- 
level penicillinase LLP, MIC=MBC of AMX=256 nig/L, 
MIC=MBC of AMX-CA (2 mg/L)=4 rng/L, and high-level peni- 
cillinase HLF', MIC=MBC of AMX=256 mg/L, MIC MBC of 
AMX-CA=256 mg/L) were used in this study The kinetics ofbacte- 
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ricidal activity of serum from treated pigs were investigated at the 
following PK times: 0.5, 0.75, 1, 2, 5, 8 and 12 h for both strains. 
For LLP E. coli, a very rapid (after 1-3 h contact) and very deep 
(down to 6 log decrease of starting inoculuni) bactericidal effect is 
obtained with each serum sample up to 12 h, even when concentra- 
tions of both drugs fall below the theoretically eficient levels. For 
HLP E. coli, a 6 log decrease of inoculum is obtained during 1 h after 
drug administration in pigs. Thus, a much greater than expected 
bactericidal effect is obtained with AMX-CA 1.1 g against B-lacta- 
mase-positive E .  coli in this micro-pig model that thoroughly mimics 
the 2.2-g IV regimen in humans. 
Jp78oj Killing activities of carbapenems 
N. Aswapokee', S. Tiengrim', B. Charoensook'. Departments of 
'Medicine and 'Preventive and Social Medicine, Siriraj Hospital, 
Bangkok, Thailand 
Objectives: To compare killing activities and suppression of 
regrowth of Paeruginosa between two parenteral carbapenems. 
Methods: We studied time-kill curve characteristics of imipenem 
and meropenem against 3 different strains of Paeruxinosa, namely, 
highly susceptible, moderately susceptible and less susceptible strains, 
using different antimicrobial concentrations. Initial inocula of approx- 
imately lo5 CFU of I? aenrginosa strains were grown in 1 MIC, 2 MIC 
and 4 MIC of imipenem and meropenem. Inocula were counted at 
every hour for 6 h and at overnight incubation. 
Results: The results show that initial killing, defined as 100-fold 
(99%) reduction of initial inoculum (No), were slow (approximately 
6 h) for both imipenem and meropenem, and were concentration 
independent, for highly susceptible and moderately susceptible 
strains. The less susceptible strain was 99% killed only by imipenem 
with concentrations 2 and 4 times MIC, and meropenem with a 
concentration of 4 MIC. Regrowth was seen at 24 h with low 
concentrations (MIC, 2 MIC) ofboth carbapenems for all strains, but 
less so with high concentration (4 MIC). 
Conclusions: The killing activities of iniipeneni and meropenem 
were similar for I? aeruginosa which were highly and moderately 
susceptible, and imipenem was better than meropenem for less 
susceptible strains. All strains show regrowth, indicating that syner- 
gism with a second antibiotic is necessary Initial killing was concen- 
tration independent. Regrowth, however, seems to be preventable by 
concentrations of 4 MIC. 
Lp7811 Antibiotic release from removed temporary hip 
spacers 
E. Bertazzoni MineUi', A. Benini', B. Magnan', R. Biscaglia', P. 
Bartolozzi'. 'Institute of Pharmacology, 'Orthopedic Clinic, University of 
Verona, Verona, Italy 
Objectives: To determine if the temporary hip prostheses (spacers) 
removed 4-5 months after implantation for treatment of T H R  (total 
hip replacement) infections can release the antibiotic from poly- 
methylmethacrylate cement. 
Methods: Seven spacers impregnated with gentamicin (GM, 1.8% 
concentration) were removed from 7 patients (mean age 69.6 years) 
4-6 months following implantation. The elution of antibiotic from 
spacers was performed by immersion in defined volumes of phos- 
phate buffer at 37OC for 1, 3 and 10 days. Antibiotic concentrations 
were determined by microbiological assay (agar-well diffusion 
method, B. subtilis spore suspension as test organism) and by polar- 
ized fluorimetry (TDx). 
Results: Gentamicin was still present 4-6 months following 
implantation. The release of GM spacers (surface area corresponding 
to 250 cm2) during 10 days of elution was 1.g2.0 mg. The concen- 
trations of GM ranged from 3.8 mg/cm2 to 8.7 mg/cm2. The release 
corresponded to 6-14% of the initial GM concentration, before 
spacer implantation. The antimicrobial activity was quite constant 
during the period of elution. The sensitivity of the microbiological 
method was higher than that of the TDx assay 
Conclusions: The concentration of GM released 4-6 months 
after implantation can be considered to be still effective against 
susceptible bacteria, i.e. Streptococcus and some S. aureus strains, but 
borderline against less susceptible bacteria, such as S. aureus, Sepider- 
midis, E. coli and other Gram-negative bacilli. 
lp7821 Pharmacology of azithromycin and 
clarithromycin against resistant pneumococci 
G. Amsden. Clinical Pharmacology Research Center, Bassetf Healthcare, 
Cooperstown, Nk; USA 
Objectives: To characterize the serum and intracellular pharmaco- 
kinetics of azithromycin (AZ) and clarithromycin (CLAR), and 
project their pharmacodynamic activity against both sensitive and 
resistant pathogens. 
Methods: Twelve healthy volunteers were administered A 2  500 
mg PO, q24h for 3 days and had aggressive serum, neutrophil and 
monocyte sampling conducted during and for 7 days after the end of 
dosing. WBCs were harvested utilizing a mono-poly resolving 
media, and both serum and WBC samples were assayed for AZ 
concentrations using an HPLC assay with electrochemical detection 
(CV less than 10%). Pharmacokinetic parameters, as well as serum 
and WBC exposure curves, were modeled using the TopFit v.2.0 
software. The serum and WBC pharmacokinetics and exposures for 
a 10-day course of CLAR 500 mg PO q12h were simulated from 
data derived from the published literature. Pharmacodynainic activ- 
ities of both compounds versus sensitive and resistant S. pneumoniae 
isolates were estimated, comparing the intraphagocytic drug conceii- 
trations to pathogen MICS. 
Results: Despite low serum concentrations, it appears that both 
agents should be active against resistant pneumococci upon phago- 
cytosis. Clinical MIC breakpoints of 8 mg/L for CLAR and 32 mg/L 
for AZ may be more clinically relevant than currently utilized labo- 
ratory breakpoints. 
Conclusions: With the pharmacodynamics of AZ (AUC/MIC) 
and CLAR (time above MIC) optimized upon organism phagocyto- 
sis, this may explain the disparity between high incidences of in vitro 
resistance but lack of clinical failure reports. 
lp7831 Pharmacodynamics of fluconazole 
D. Andes, M. van Ogtrop. Infectious Diseases, University o f  Wisconsin, 
Madison, USA 
In these experiments we determined the pharmacodynamic parame- 
ter and the magnitude of that parameter's predictive capability with 
respect to the efficacy of fluconazole in treatment of disseminated 
candidiasis. We utilized a neutropenic murine model of disseminated 
Candida albicans to characterize the time course activity of flucona- 
zole. At the start of therapy mice had lo4 CFU/kidneys. An Em,, 
dose-response model was used to determine the dose producing 50% 
of the maximal microbiological effect (ED5o). Quantitation of colony 
counts in kidneys after 24 h of therapy with a wide range of doses 
and three dosing intervals were utilized in therapy over a 24-h period. 
The dose required to achieve 50% of the maximal effect was similar 
A b s t r a c t s  295 
for each of the dosing intervals studied, supporting AUC/MIC as the 
parameter predicting eiilcacy of fluconazole. Similar studies were 
performed using Candida albicans with fluconazole MICs in the 
susceptible-dose-dependent range (16-32 mg/L). We found that the 
niagnitude of the AUC/MIC ratio required to reach EDSO was simi- 
lar for all three organisms studied, ranging from 15 to 25. When one 
considers the pharniacokinetic; of fluconazole in humans, doses of 
400-800 mg/day would achieve AUCIMIC ratios in the range of 
15-20 for organitnis with MICs of 16-32 mg/L. In the recent 
NCCLS breakpoint guidelines publication, 90%) clinical success was 
observed when these doses were used in the therapy for organisms 
with MICs in the range of 16-32 mg/L. These studies support 
current NCCLS breakpoint guidelines. 
/p7841 Postantibiotic effect (PAE) of 
quinupristin-dalfopristin (0-D) against MSSA 
in comparison to other antibacterial agents 
E. Pfeil, B. Wiedemann. Pharniaceutical Microbiology, University of 
Borin, Bonn, Gcrniany 
Objectives: Antibiotics often show an excellent PAE with expo- 
nentially growing cultures. In vivo bacteria often grow less efficiently 
In this study we compared the L’AE of Q-D, the first parented strep- 
togramin, with that of vancomycin (VAN), moxifloxacin (MOX), 
gentaniicin (GEN), roxithromycin (KOX), cefotaxime (CEF), and 
ceftriaxone (CET) against an e.rcponentially growing (EC) and static 
bacterial culture (SC) of S. anreus. 
Methods: The PAE wat evaluated for one MSSA. The PAE was 
defined as the time required foi- the viable counts to increase by one 
log 10. The time ofexposure ofthe bacteria to the drugs was 1 h for 
EC and 1 h and 4 h for SC. The concentration of the antibiotics was 
1 ,  2 and 4 times the MIC. 
Results: E C  The PAE of Q-D ranged from 2.7 to 5.3 h, of GEN 
from 1.5 to 3.2 h, o f R 0 X  from 1.4 to 1.8 h, and ofMOX from 0.7 
to 1.7 h; for VAN, CEF and CET it was between 0.4 and 1.0 h. S C  
Under these conditions only Q-D shows a PAE. After an exposition 
time of 1 h, values ranged from 0.6 h (1 XMIC), 1.1 h (2XMIC) and 
1.6 h ( 4x MIC) but after 4 11 they were 1.7 h (IXMIC), 5.5 h 
(2XMIC), and 6.7 h (4XMIC). Further studies denionstrated that 
the exposition time it a more important parameter in determining 
PAE (SC) than the antibiotic concentration. 
Conclusions: Q-D shows the highest PAE of the tested antibi- 
otics against exponentially growing cultures. Furthermore, Q-D is 
the only antibiotic with a significant PAE against static bacteria 
culture. 
Objectives: To investigate the survival of lactic acid-producing 
bacteria in different formulations after incubation in pH 1.2 for 1 h 
(the pH and minimum time described by the European Phainacopeia 
for tcsting gastroresistant drugs). 
Materials and methods: The following six products were tected: 
Baktoflora, Bifolac, Idoform, Paraghurt, Synibioflor and Symbio- 
plex. The capsules/tablets were incubated in 5 niL of 0.1 M citric 
acid, pH 1.2, at 37OC for 1 h while being gently shaken, followed by 
neutralization to pH 7.4-7.5. Then the capsules/tablets were homog- 
eiiized and the nnmber of viable bacteria was nieasured by colony 
count following aerobic and anaerobic incubation and compared to 
the original content of bacteria. 
Results: After 60 min the following reduction of viable bacteria 
was seen (logiir): Baktoflora 1.7, Bifolac 0.2, Idoform 0.7, Paraghurt 
3.7, Synibioflor 6.0 and Symbioplex 8.5. 
Conclusions: After 60 min of incubation of the capsules/tablets 
at pH 1.2, only two products (Bifolac and Idoform) had less than 1 
log reduction in the number of viable bacteria, wherras in the rest of 
the products a significant reduction of viable bacteria was obterved. 
lp7861 Tissue concentration of cefuroxime (CEF) 
during preoperative antibiotic prophylaxis (AP) 
in abdominal surgery 
A.A. Muckonin, V.G. Pleshkov, N.N. Sudilovri-suskaya. N.N. 
Lebedeva, L.S. Stratchounski. General Surpry, Sinolerisk Stare Medical 
A cadem y, Smolrris k, Russian Federa tion 
Objectives: To determine the concentration of CEF in seruni (S), 
subcutaneous adiposal tissue (SAT) and preperitoneal fat (I’F) after 
AP 
Methods: 12 patients, 3 males and 9 females, were included in 
the study All patients have undergone cholecystectoniy of laparo- 
tomy (9) or mini-laparotomy (3). The age was 57? 13 yearc, and the 
weight 81 ? 19 kg. CEF was administered by intravenous bolus injec- 
tion (IVB) at a dose of 1.5 g 40 min before the incision. The venous 
blood was collected every 15 min over a period of 120 nun. The 
samples of SAT and PF were collected every 15 min after beginning 
the operation for a period of 60 inin. The concentration of CEF was 
determined by bioassay with strain E. coli MB 3804. 
Results: The concentrations of CEF are shown in the following 
table: 
Results: The concentration of CEF are shown in the followng table 
40 55 70 85 100 120 t, min 10 25 
Concentration, ms/l (MGD ) 
S 77.3.tl0.7 56,5211.9 41.0~11.9 38.8212.6 32.89.8 28.3t7.8 2 5 2 5 . 4  22.75.5 
SAT - 
PF - 
- 8.43.6 6.451.7 5.6.0.6 5.2.0.6 4.996 - 
- 11.2.6.7 6.75.7 53.09 5921.5 5.1.0.5 - 
[p7851 Effect of low pH on survival of bacteria in oral Conclusions: After IVB of CEF for AP at S and the surround- 
ing incision tissues here are observed the concentrations of CEF 
exceeding minimal inhibitory concentration (MIC) of the main 
pathogens of the wound infection (S. atmiis, S. epidermididis, Strepto- 
coccus spp., E. rolr]. The trend to reduce the concentrations of CEF 
formulations 
L. Corneliussen, K.  Skov, E Esperten. Division qf MicrobioloB, 
Statens Serirrn Imt i t t r t ,  Copewkaqtw, Derirnark . .  .. 
in tissues to the end of operation require consideration of the other 
regimens of AP alternative to IVB. 
Background: A range of lactic acid-producing bacteria are included 
in oral formulations. Such products, which often are not pharma- 
ceuticals, are used with the purpose of modulation of the gastroin- 
testinal microflora. However, do there formulations protect the 
bacterial content against the low pH of the gastric mucosa? 
